Dynamic Response Genes in CD4+T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis
2016 (English)In: Cell reports, ISSN 2211-1247, E-ISSN 2211-1247, Vol. 16, no 11, 2928-2939 p.Article in journal (Refereed) Published
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS and has a varying disease course as well as variable response to treatment. Biomarkers may therefore aid personalized treatment. We tested whether in vitro activation of MS patient-derived CD4+ T cells could reveal potential biomarkers. The dynamic gene expression response to activation was dysregulated in patient-derived CD4+ T cells. By integrating our findings with genome-wide association studies, we constructed a highly connected MS gene module, disclosing cell activation and chemotaxis as central components. Changes in several module genes were associated with differences in protein levels, which were measurable in cerebrospinal fluid and were used to classify patients from control individuals. In addition, these measurements could predict disease activity after 2 years and distinguish low and high responders to treatment in two additional, independent cohorts. While further validation is needed in larger cohorts prior to clinical implementation, we have uncovered a set of potentially promising biomarkers.
Place, publisher, year, edition, pages
CELL PRESS , 2016. Vol. 16, no 11, 2928-2939 p.
IdentifiersURN: urn:nbn:se:liu:diva-132056DOI: 10.1016/j.celrep.2016.08.036ISI: 000383882300014PubMedID: 27626663OAI: oai:DiVA.org:liu-132056DiVA: diva2:1038462
Funding Agencies|Swedish Research Council [K2013-61X-22310-01-4, K2013-61X-07488-28-5, 2015-03495]; Medical Research Council of Southeast Sweden (FORSS); Swedish Foundation for MS Research; NEURO Sweden; Centre for Industrial IT (CENIIT); Ake Wiberg Foundation; Knut and Alice Wallenberg Foundation; Swedish Brain Foundation; AFA foundation; Margareta af Ugglas foundation; Swedish Society for Medical Research; Biogen; Novartis; Genzyme; Merck; Allmiral; Biogen Idec2016-10-182016-10-172016-11-11